Skip to main content
Eye logoLink to Eye
letter
. 2019 Oct 23;34(3):600–602. doi: 10.1038/s41433-019-0624-7

Validation of RetmarkerAMD as a semiautomatic grading software for AMD

João Pedro Marques 1,2,3,, João Pires 2, Jorge Simão 1, Marco Marques 3, João Q Gil 1,2,3, Inês Laíns 2,4, Dalila Alves 3, Sandrina Nunes 3, Maria Luz Cachulo 1,2,3, John B Miller 4, Demetrios G Vavvas 4, Joan W Miller 4, Deeba Husain 4, Rufino Silva 1,2,3
PMCID: PMC7042224  PMID: 31645672

Introduction

RetmarkerAMD® (Retmarker SA, Coimbra, Portugal) is a semiautomatic grading software developed specifically for age-related macular degeneration (AMD). Pilot studies demonstrated higher sensitivity and specificity than manual grading and attested its capacity to decrease grading time and identify more AMD features, thus reducing human error [1]. The aim of this study was to validate RetmarkerAMD® as an AMD grading tool, by comparing it with an already validated and widely used platform—Topcon IMAGEnet2000®.

Methods

Multicentre, cross-sectional study. A set of 202 colour fundus photographs (CFPs) randomly selected from a pool of eyes with and without AMD were used. All images had previously been graded by a senior retina specialist (gold standard) using Topcon IMAGEnet2000®. Two certified graders with different experience independently classified all CFPs using both platforms (Fig. 1; Supplemental Fig. 1) after brightness, contrast and colour balance standardization [2]. Conversion of AMD staging from the Rotterdam classification to the AREDS [3] classification (Supplemental Tables 1 and 2) was achieved to allow a comparison between platforms.

Fig. 1.

Fig. 1

Real-time demonstration of the grading process using RetmarkerAMD®. a First, it is necessary to manually identify the fovea and establish the optic disc diameter (blue dot and arrows, respectively) to achieve the calibration. The software then generates an automated grid b according to International Grading System for AMD. c Fundus abnormalities including drusen, pigmentary changes, geographic atrophy and neovascular AMD can be quantified using free-forms or pre-defined circles (63, 125, 175, 250 and 500 μm). d Grading results (including automatic AMD staging according to the Rotterdam classification—Supplementary Table 1) are depicted on screen and can be exported to a Microsoft Excel® file for posterior statistical analysis. RetmarkerAMD® also allows to categorically quantify the number (0, 1–9, 10–19, ≥20) and area (<1%, <10%, <25%, <50%, ≥50%) of drusen, and additionally to determine the real number and area of drusen (μm2), total or by semi-field

Intra- and inter-grader agreement was evaluated by the percentage of agreement and the weighted Kappa coefficient considering linear weights [4].

Results

The inter-grader analysis for all features analysed with RetmarkerAMD® is shown in Table 1. For AMD staging alone, an almost perfect agreement (93.0%; Kappa = 0.95, p < 0.001) was observed. The same was true for AMD staging using Topcon IMAGEnet2000® (90.1%; Kappa = 0.87, p < 0.001). Both graders showed a high agreement with the gold standard (90.1%; Kappa = 0.88, p < 0.001 and 87.1%; Kappa = 0.86, p < 0.001 for graders 1 and 2, respectively). Regarding the inter-modality analysis (Supplemental Table 3), a 76.8% agreement (Kappa = 0.73, p < 0.001) and a 70.8% agreement (Kappa = 0.67, p < 0.001) was observed for graders 1 and 2, respectively.

Table 1.

Inter-grader (grader 1 vs. grader 2) agreement analysis using the RetmarkerAMD® software

Variable % Agreement Kappa coefficient Strength of agreement P-value
Number of drusen 85.2% 0.86 Almost perfect <0.001
Number of drusen <63 μm 82.7% 0.83 Almost perfect <0.001
Number of drusen 63–125 μm 76.7% 0.78 Substantial <0.001
Number of drusen >125 μm 82.7% 0.80 Substantial <0.001
Predominant drusen type within the outer circle 83.2% 0.25 Fair <0.001
Total area occupied by drusen 90.0% 0.75 Substantial <0.001
Area covered by drusen in subfield 1 85.2% 0.84 Almost perfect <0.001
Area covered by drusen in inner circle 83.0% 0.69 Substantial <0.001
Area covered by drusen in outer circle 86.5% 0.66 Substantial <0.001
Confluence of drusen 48.8% 0.32 Fair <0.001
Hyperpigmentation 97.0% 0.93 Almost perfect <0.001
Hypopigmentation 99.5% 0.98 Almost perfect <0.001
Geographic Atrophy 99.5% 0.96 Almost perfect <0.001
Neovascular AMD 100.0% 1.00 Perfect <0.001
Stage AMD 93.0% 0.95 Almost perfect <0.001

Kappa coefficient and its correspondent strength of agreement according to Landis & Koch: <0.00 = poor; 0.00–0.20 = slight; 0.21–0.40 = fair; 0.41–0.60 = moderate; 0.61–0.80 = substantial; 0.81–0.99 = almost perfect; 1.00 = perfect

AMD age-related macular degeneration

Discussion

This study aimed to validate RetmarkerAMD® as a semiautomatic grading software for the fundoscopic changes associated with AMD. We used CFP because of its reproducibility and loyalty to clinical fundoscopy, making it easy to extrapolate results to clinical practice.

Regarding AMD staging, a considerably high agreement was found in both platforms. Subtle differences between graders may have been influenced by a higher level of experience of grader 1. In fact, grader experience is a factor used across studies to justify discrepancies on agreement analyses [5].

The comparison of intra-grader analyses using the two software systems revealed a substantial agreement. The clear overlap between early and intermediate stages where subtle and somewhat arbitrary differences are seen may have influenced the results. Classification bias may also have been introduced due to the conversion of the Rotterdam classification into the AREDS classification.

Despite several advantages, RetmarkerAMD® presents some limitations. First, it demands lesion identification by a human grader, a rate limiting and fatigable process. Second, this platform is not prepared to grade optical coherence tomography, a rapidly growing technology with promising outcomes in automatic and semiautomatic AMD grading.

By conducting a carefully planned study, we were able to demonstrate that RetmarkerAMD® is a reliable and consistent semiautomated grading tool for AMD. The validation of RetmarkerAMD® may prompt its use both in clinical studies and in clinical trials.

Supplementary information

Supplemental Table 1 (14.6KB, docx)
Supplemental Table 2 (13.4KB, docx)
Supplemental Table 3 (16.8KB, docx)
Supplemental Figure (3MB, tif)
Supplemental Figure 1 (13.4KB, docx)

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Footnotes

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

The online version of this article (10.1038/s41433-019-0624-7) contains supplementary material, which is available to authorized users.

References

  • 1.Marques JP, Costa M, Melo P, Oliveira CM, Pires I, Cachulo ML, et al. Ocular risk factors for exudative AMD: a novel semiautomated grading system. ISRN Ophthalmol. 2013;2013:464218. doi: 10.1155/2013/464218. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Tsikata E, Lains I, Gil J, Marques M, Brown K, Mesquita T, et al. Automated brightness and contrast adjustment of color fundus photographs for the grading of age-related macular degeneration. Transl Vis Sci Technol. 2017;6:3. doi: 10.1167/tvst.6.2.3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Age-Related Eye Disease Study Research G. The Age-Related Eye Disease Study system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the Age-Related Eye Disease Study Report Number 6. Am J Ophthalmol. 2001;132:668–81. doi: 10.1016/S0002-9394(01)01218-1. [DOI] [PubMed] [Google Scholar]
  • 4.Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159–74. doi: 10.2307/2529310. [DOI] [PubMed] [Google Scholar]
  • 5.Scholl HP, Peto T, Dandekar S, Bunce C, Xing W, Jenkins S, et al. Inter- and intra-observer variability in grading lesions of age-related maculopathy and macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2003;241:39–47. doi: 10.1007/s00417-002-0602-8. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplemental Table 1 (14.6KB, docx)
Supplemental Table 2 (13.4KB, docx)
Supplemental Table 3 (16.8KB, docx)
Supplemental Figure (3MB, tif)
Supplemental Figure 1 (13.4KB, docx)

Articles from Eye are provided here courtesy of Nature Publishing Group

RESOURCES